Stevanato Group (NYSE:STVN) Shares Gap Down – What’s Next?

Stevanato Group S.p.A. (NYSE:STVN) gapped down before the market opened on Wednesday . The stock had previously closed at €21.76 ($23.91), but opened at €21.20 ($23.30). Stevanato Group shares last traded at €21.53 ($23.66), with a volume of 10,034 shares.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Wolfe Research began coverage on Stevanato Group in a research note on Friday, December 13th. They set an “outperform” rating and a $28.00 target price for the company. William Blair restated an “outperform” rating on shares of Stevanato Group in a research note on Friday, March 7th. Bank of America upped their target price on shares of Stevanato Group from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, December 13th. Morgan Stanley restated an “equal weight” rating and set a $23.00 price objective (down previously from $24.00) on shares of Stevanato Group in a report on Tuesday, December 3rd. Finally, UBS Group reduced their target price on shares of Stevanato Group from $24.00 to $23.50 and set a “neutral” rating for the company in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of €27.75 ($30.49).

Stevanato Group Stock Performance

The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21. The firm has a market cap of $6.53 billion, a P/E ratio of 45.87, a PEG ratio of 7.18 and a beta of 0.60. The stock’s 50 day moving average is €21.12 and its two-hundred day moving average is €20.58.

Stevanato Group (NYSE:STVN) last released its quarterly earnings data on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share for the quarter, meeting the consensus estimate of €0.20 ($0.22). Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. The company had revenue of €352.68 million for the quarter, compared to analyst estimates of €346.26 million. As a group, equities analysts predict that Stevanato Group S.p.A. will post 0.5 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Natixis Advisors LLC increased its position in shares of Stevanato Group by 20.3% during the 3rd quarter. Natixis Advisors LLC now owns 51,343 shares of the company’s stock worth $1,027,000 after purchasing an additional 8,669 shares in the last quarter. Thrivent Financial for Lutherans boosted its stake in Stevanato Group by 67.6% in the third quarter. Thrivent Financial for Lutherans now owns 2,784,912 shares of the company’s stock valued at $55,698,000 after acquiring an additional 1,123,104 shares during the last quarter. Lindenwold Advisors INC boosted its position in shares of Stevanato Group by 13.5% in the 3rd quarter. Lindenwold Advisors INC now owns 11,930 shares of the company’s stock worth $239,000 after purchasing an additional 1,415 shares during the last quarter. Raymond James Trust N.A. boosted its holdings in Stevanato Group by 22.6% during the third quarter. Raymond James Trust N.A. now owns 12,556 shares of the company’s stock worth $251,000 after buying an additional 2,317 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Stevanato Group by 16.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 294,235 shares of the company’s stock valued at $5,885,000 after acquiring an additional 42,629 shares during the last quarter.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.